Aurum Biosciences is developing novel therapeutics and diagnostics in areas of unmet clinical need

Aurum Biosciences Ltd is a UK based clinical stage biopharmaceutical company developing novel oxygen carriers for use as therapeutics and diagnostics, initially for Acute Ischaemic Stroke (AIS) and Inflammation Imaging. Follow-on indications include heart disease, cardiac arrest, oncology, spinal cord injury (SCI), and traumatic brain injury (TBI).

Aurum’s lead product ABL-101 has undergone significant pre-clinical development and has completed early phase 1 and 2a human studies. ABL-101, is planned for phase 2a trials in stroke and inflammation imaging in 2026